Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash & Current Investments: 2023-2025

Historic Cash & Current Investments for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $476.9 million.

  • Zenas BioPharma's Cash & Current Investments rose 32.43% to $476.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 176.05%. This contributed to the annual value of $350.8 million for FY2024, which is 516.93% up from last year.
  • Zenas BioPharma's Cash & Current Investments amounted to $476.9 million in Q3 2025, which was down 5.41% from $504.2 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Cash & Current Investments registered a high of $504.2 million during Q2 2025, and its lowest value of $37.2 million during Q1 2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $350.8 million (2024), whereas its average is $274.7 million.
  • Data for Zenas BioPharma's Cash & Current Investments shows a peak YoY soared of 1,054.74% (in 2025) over the last 5 years.
  • Zenas BioPharma's Cash & Current Investments (Quarterly) stood at $56.9 million in 2023, then soared by 516.93% to $350.8 million in 2024, then soared by 32.43% to $476.9 million in 2025.
  • Its Cash & Current Investments was $476.9 million in Q3 2025, compared to $504.2 million in Q2 2025 and $430.0 million in Q1 2025.